DARPin® candidates demonstrate 100% survival in an aggressive viral challenge model Data support utility of anti-COVID-19 DARPin® candidates as potent therapeutics First-in-human clinical trial initiation of MP0420 planned for November 2020 Zurich-Schlieren, Switzerland, October 6, 2020.

MP0317 activates multiple antitumor immune cell types in vitro when in the presence of tumor stroma associated FAP MP0317 mouse surrogate localizes to FAP-expressing tumors and induces strong and durable anti-tumor responses without systemic toxicity, and demonstrates strong anti-tumor immune

High yields in bacterial fermentation systems support ability of DARPin® manufacturing to rapidly scale for global supply First and only, tri-specific antiviral demonstrating potential best-in-class potency in vivo First-in-human clinical trial initiation planned for November 2020 Zurich-Schlieren,

Zurich-Schlieren, Switzerland, September 11, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Patrick Amstutz, chief executive officer, will be presenting at the HC

Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial  in vitro  and  in vivo  data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen.

Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use Purchase of these doses may occur following appropriate marketing authorization Multi-specific antiviral

Zurich-Schlieren, Switzerland, July 20, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent

Partnership secures initial clinical and commercial-scale microbial manufacturing capacity The only tri-specific antiviral protein in development, with potential best-in-class potency Clinical studies planned for Q4 2020 Zurich-Schlieren, Switzerland, July 9, 2020.

Proceeds  from the Offering will help accelerate development of the SARS-CoV-2 antiviral candidate, MP0420, as well as early stage clinical and preclinical pipeline assets Zurich-Schlieren, Switzerland, July 7, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is

Proceeds used to accelerate early stage pipeline, inclusive of MP0310, MP0317 and the SARS-CoV-2 antiviral program MP0420 Zurich-Schlieren, Switzerland, July 6, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein